![]() In conclusion, this study pooled the main outcomes and showed that MSC therapy could significantly decrease VAS and ODI scores in patients with DDD. However, our further statistical analysis showed that MSC therapy may induce AE of TEAE related to study treatment (OR=3.05, 95%CI=1.11~8.40, P=0.03). Adverse events (AE) of treatment-emergent adverse events (TEAE), back pain, arthralgia, and muscle spasms were not statistically significant between the two groups. Pooled analysis showed that MSC therapy has a higher ratio of patients at most thresholds but particularly at the MIC (minimally important change) (P=0.0002) and CSC (clinically significant change) (P=0.0002) in VAS and MIC (P=0.0005) and CSC (P=0.001) pain responders in ODI. The outcomes with subgroup analysis showed that MSC therapy could decrease VAS scores in 3 months (P=0.001), 6 months (P=0.01), 12 months (P=0.02), and ≥24 months (P=0.002) and ODI scores in ≥24 months (P=0.006). The Cochrane bias risk assessment tool was used to assess quality. ![]() We searched major databases using terms from the database's inception through March 2021. We conducted a meta-analysis with randomized controlled trials (RCTs) to evaluate the clinical efficacy and safety of MSC transplantation in patients with DDD. However, the clinical efficacy of MSC in the treatment of DDD still lacks clinical evidence and is controversial. For the past few years, mesenchymal stem cell (MSC) transplantation has emerged as a promising strategy for the treatment of DDD. Degenerative disc disease (DDD) can cause severe low back pain, which will have a serious negative impact on the ability to perform daily tasks or activities.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |